Form 8-K - Current report:
SEC Accession No. 0001731122-25-000427
Filing Date
2025-03-21
Accepted
2025-03-21 17:20:37
Documents
16
Period of Report
2025-03-21
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6439_8-k.htm   iXBRL 8-K 26596
2 EXHIBIT 3.1 e6439_ex3-1.htm EX-3.1 1784
3 GRAPHIC img_001.jpg GRAPHIC 3824633
4 GRAPHIC img_002.jpg GRAPHIC 1162056
  Complete submission text file 0001731122-25-000427.txt   7060912

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE vrpx-20250321.xsd EX-101.SCH 3027
6 XBRL LABEL FILE vrpx-20250321_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE vrpx-20250321_pre.xml EX-101.PRE 24173
18 EXTRACTED XBRL INSTANCE DOCUMENT e6439_8-k_htm.xml XML 3923
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

EIN.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 25761597
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)